ANI Pharmaceuticals, Inc.

What they do

ANI operates three pharmaceutical manufacturing facilities: two in Baudette, Minnesota and one in East Windsor, New Jersey, capable of producing oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company sells branded and generic prescription products and, following the September 2024 acquisition of Alimera Sciences, a retina franchise including ILUVIEN and YUTIQ. Its lead Rare Disease asset is Purified Cortrophin Gel. The Generics portfolio included more than 120 products as of December 31, 2025.

Revenue drivers

• Cortrophin Gel (Rare Disease) — Net revenues were $117.1 million in Q2 2026, up 43.5% year-over-year, making it the largest single product line; full-year 2026 guidance was adjusted to $520-$540 million.
• Generics — Net revenues were $99.1 million in Q2 2026, up 9.7% year-over-year, driven by new product launches; the company launched 12 new generics products year-to-date 2026.
• ILUVIEN and YUTIQ (Retina Franchise) — ILUVIEN net revenues were $18.7 million in Q2 2026, down 16.1% year-over-year due primarily to international shipment timing; YUTIQ promotional efforts were transitioned to ILUVIEN in Q2 2025.
• Brands and royalties — Brands net revenues were $11.8 million in Q2 2026, down 10.5%; the company also recognized $17.7 million under the Harmony Agreement, including $9.7 million of pitolisant royalties and $8.0 million of development milestone revenue.

Recent performance

Total net revenues for Q2 2026 were $266.0 million, up 25.9% year-over-year. GAAP net income available to common shareholders was $24.7 million, or $1.05 diluted GAAP income per share, with adjusted non-GAAP EBITDA of $71.6 million, up 32.4%. Cortrophin Gel drove the quarter with $117.1 million in net revenues, up 43.5%, while Generics grew 9.7% to $99.1 million. ILUVIEN declined 16.1% to $18.7 million and Brands declined 10.5% to $11.8 million. Full-year 2025 revenue was $883.4 million with net income of $78.0 million and operating cash flow of $185.2 million.

Strategy

Management is focused on expanding its Rare Disease and Brands segment, including building a dedicated sales organization for Cortrophin Gel in acute gouty arthritis flares targeting an estimated 285,000 patients, primarily through podiatrists and primary care physicians. The company continues to add generic products, expecting 10 to 15 launches per year, and launched 12 generics year-to-date 2026. Following the Alimera acquisition, ANI expanded its ophthalmology footprint beyond the U.S. through direct operations in Germany, the UK, Portugal and Ireland, plus partnerships in Europe, Asia and the Middle East. Recent financing included a $325 million term loan drawn in September 2024 and $316.25 million of convertible senior notes due 2029.

Risks

• Commercialization dependence — Cortrophin Gel and ILUVIEN may not achieve market acceptance sufficient to maintain profitability, and the company's results depend heavily on Cortrophin Gel growth.
• Supplier concentration — A limited number of suppliers provide the API for Cortrophin Gel, and several products are single-sourced or rely on third-party contract manufacturers, creating delay and compliance exposure.
• Government pricing and rebates — Medicaid rebate accruals have increased and continue to increase due to acquired branded products and authorized generics, and changes in estimates could materially affect results.
• Healthcare regulation compliance — Failure to comply with complex U.S. and foreign healthcare laws, including data protection and government price reporting, could result in substantial penalties.

Outlook

Management reaffirmed 2026 total net revenue guidance of $1,080-$1,140 million and adjusted non-GAAP EBITDA of $285-$300 million. Cortrophin Gel net revenue guidance was modestly adjusted to $520-$540 million, reflecting 50-55% growth for the full year. The company expects to recognize an additional $2.0 million in development milestone revenue in Q3 2026 from the Harmony Agreement and continues to earn low single digit royalties on pitolisant-based products. Initial gout expansion metrics were described as positive, with over 95% of reps generating multiple new patient cases.